Moomoo AI 已提取核心信息
EyePoint Pharmaceuticals officer David S. Jones is set to sell 10,104 shares of common stock on 02/02/2024, as per the latest filing. These shares, valued at an aggregate market value of $288,065.04, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This sale follows a series of transactions over the past three months where a total of 72,983 shares were sold, amounting to gross proceeds of $1,753,183.17.
EyePoint Pharmaceuticals officer David S. Jones is set to sell 10,104 shares of common stock on 02/02/2024, as per the latest filing. These shares, valued at an aggregate market value of $288,065.04, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This sale follows a series of transactions over the past three months where a total of 72,983 shares were sold, amounting to gross proceeds of $1,753,183.17.
根据最新文件，EyePoint制药公司高管戴维·琼斯定于2024年2月2日出售10,104股普通股。这些股票的总市值为288,065.04美元，于当天通过行使股票期权收购，交易涉及向发行人支付现金。此次出售是在过去三个月进行的一系列交易之后进行的，共出售了72,983股股票，总收益为1,753,183.17美元。
根据最新文件，EyePoint制药公司高管戴维·琼斯定于2024年2月2日出售10,104股普通股。这些股票的总市值为288,065.04美元，于当天通过行使股票期权收购，交易涉及向发行人支付现金。此次出售是在过去三个月进行的一系列交易之后进行的，共出售了72,983股股票，总收益为1,753,183.17美元。
有用
没用
